Goldenberg Ronald M, Gilbert Jeremy D, Houlden Robyn L, Khan Tayyab S, Makhija Sapna, Mazer C David, Trinacty Jill, Verma Subodh
LMC Diabetes & Endocrinology, Concord, Canada.
Division of Endocrinology and Metabolism, Sunnybrook Health Sciences Centre, Toronto, Canada.
Curr Med Res Opin. 2025 Mar;41(3):403-419. doi: 10.1080/03007995.2025.2458538. Epub 2025 Jan 31.
The GLP-1 receptor-based agonists (GLP-1RAs) and SGLT2 inhibitors (SGLT2i) are major twenty first century breakthroughs in diabetes and obesity medicine but there are important safety considerations regarding the perioperative and periprocedural management of individuals who are treated with these agents. GLP-1RAs have been linked to an increased risk of retained gastric contents and pulmonary aspiration while SGLT2i can be associated with diabetic ketoacidosis. This manuscript provides a narrative review of the available evidence for perioperative and periprocedural risks in people prescribed GLP-1RAs and SGLT2i. The authors provide expert opinion-driven recommendations and algorithms on how to safely manage GLP-1RAs and SGLT2i under perioperative/periprocedural settings.
基于胰高血糖素样肽-1受体的激动剂(GLP-1RAs)和钠-葡萄糖协同转运蛋白2抑制剂(SGLT2i)是21世纪糖尿病和肥胖医学领域的重大突破,但对于接受这些药物治疗的个体,在围手术期和围操作期管理方面存在重要的安全考量。GLP-1RAs与胃内容物残留和肺误吸风险增加有关,而SGLT2i可能与糖尿病酮症酸中毒相关。本文对使用GLP-1RAs和SGLT2i的患者围手术期和围操作期风险的现有证据进行了叙述性综述。作者提供了基于专家意见的建议和算法,以指导如何在围手术期/围操作期安全管理GLP-1RAs和SGLT2i。